Chief Executive Officer
Mr. Garanzini has more than 25 years of marketing experience in the pharmaceutical and Medical Device industries. Before joining CavtheRx he was the Chief Commercial Officer for EyeGate Pharmaceuticals a late-stage specialty pharmaceutical and drug delivery company focused on developing and commercializing products for treating diseases and disorders of the eye. Prior to that, he was the Global Marketing Therapy Leader for the Glaucoma Portfolio at Santen, where he was responsible for providing strategic direction to advance glaucoma products, including the acquisition and integration of the InnFocus MicroShunt. Also during his time at Santen, Mr. Garanzini served as their Head of Marketing, Europe where he played a key role in the integration of the Merck Ophthalmic products, establishing operations throughout Western Europe and ultimately led the total portfolio of glaucoma, dry eye and retinal disease products. Previously, Mr. Garanzini was the Senior Director of Global Marketing, Ophthalmology at Merck, where he was in charge of overseeing strategic planning, medical education, opinion leader relations and co-promotion alliances on a global basis while also having specific geographical responsibility for Europe. Earlier in his career at Merck, Mr. Garanzini held two non-ophthalmic product-specific roles, as U.S. Director of Marketing for Levitra and Asmanex in the Primary Care markets where he gained important DTC experience. Mr. Garanzini has also held sales and marketing positions in Pharmacia’s ophthalmology division, where he was part of the team responsible for the launch and growth phase of Xalatan and time managing surgical products used in cataract and glaucoma surgery. Mr. Garanzini holds a B.S. in Engineering from Michigan State University.
Ralph Bradshaw, PhD
Chairman of the Board
Ralph A. Bradshaw received degrees in chemistry and biochemistry from Colby College (1962) and Duke University (1966), respectively, with additional research training at Indiana University and the University of Washington. He served on the faculties of Washington University School of Medicine, St. Louis (1969-82), the University of California, Irvine (1982-2006) and the University of California, San Francisco (2006-2015). He is currently Professor Emeritus at UCI and Professor of Pharmacology at the University of California, San Diego. In addition to membership in many learned societies, he has served as president of the Federation of American Societies for Experimental Biology (FASEB) (1995-96), treasurer of the American Society for Biochemistry and Molecular Biology (1991-97) and was the founding president of the Protein Society (1986-87). He has also been a member of over twenty editorial boards, and was Editor-in-Chief or Associate Editor of several of these, including TIBS, Protein Science and the Journal of Biological Chemistry. In 2000, he started Molecular and Cellular Proteomics, serving as Editor until 2013, and is presently Editor-in-Chief of FASEB BioAdvances. He has founded four biotechnology companies and is presently a consultant to Trefoil Therapeutics. Among other honors, he received the Passano Foundation Young Scientist Award (1976), the gold medal of the Italian National Research Council (CNR) (1986), the Australian Society of Medical Research Gold Medal (1999) and the HUPO Distinguished Achievement Award (2016). His research interests have been on the structure and function of proteins and peptides.
William Sessa, PhD
Chief Scientific Officer
Dr. William (Bill) Sessa, Ph.D. serves as Vice Chairman and Professor of the Department of Pharmacology at the Yale School of Medicine. Dr. Sessa has achieved national and international recognition for the development and application of basic cellular and molecular biological techniques to physiologically important questions in the cardiovascular system. Dr. Sessa serves as Director of the Vascular Biology and Transplantation Program at Yale University School of Medicine. He serves as a Director of New Haven Pharmaceuticals, Inc. He has been a Member of Scientific Advisory Board of Cardium Therapeutics Inc. since November 30, 2006. He also serves as a Member of Scientific Advisory Board at Antibe Therapeutics Inc. He served as a Member of Scientific Advisory Board at N30 Pharmaceuticals, LLC since April 2009. Dr. Sessa was recognized by a number of honors including the John J. Abel Award in Pharmacology from the American Society of Pharmacology and Experimental Therapeutics and the Robert Berne Distinguished Lectureship from the American Physiological Society. Dr. Sessa received a Bachelor's Degree in Pharmacy from the Philadelphia College of Pharmacy and Sciences, an M.S. from the University of Rhode Island and a Ph.D. from New York Medical College. Dr. Sessa conducted post-doctoral work at the William Harvey Research Institute in London and the University of Virginia School of Medicine.
Dan is responsible for evaluating investment opportunities, structuring investments and monitoring portfolio companies through active board participation. Dan has led or assisted with CI’s investments in AxioMx (acquired by Abcam); Affomix (acquired by Illumina); CyVek (acquired by Bio-Techne); Cara Therapeutics (NASDAQ: CARA); HistoRx (acquired by Genoptix); Melinta Therapeutics, formerly Rib-X (NASDAQ: MLNT); RemoteReality (acquired by RTI); Biohaven Pharmaceuticals (NYSE: BHVN); and Arvinas (NASDAQ: ARVN). Dan contributes to CI’s expertise in biotech with more than 10 years in the industry. He was previously employed by successful former CI portfolio company CuraGen Corporation. While at CuraGen, Dan held a variety of scientific and operational management positions in research and development, technology assessment and implementation of next-generation scientific technologies that supported CuraGen’s growth from a genomic and proteomic platform company into a biopharmaceutical firm dedicated to advancing its protein, antibody and small-molecule therapeutics.